SOPHiA GENETICS CEO sells 16,631 shares in plan

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH. The shares were sold on April 10 and 13, 2026 at weighted average prices around $4.72–$4.76 per share.

Footnotes state these transactions were effected under a pre-established Rule 10b5-1(c) trading plan to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, and are not discretionary trades. After these sales, Camblong continues to hold 3,707,569 ordinary shares directly.

Insider Trade Summary 10b5-1

Net Seller: 16,631 shares

Net Sell 3 txns

Insider Camblong Jurgi

Role Chief Executive Officer

Sold 16,631 shs ($79K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	4,399	$4.7641	$21K
Sale	Ordinary Shares	8,500	$4.718	$40K
Sale	Ordinary Shares	3,732	$4.718	$18K

Holdings After Transaction: Ordinary Shares — 3,707,569 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.64 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 16,631 shares Sale price 04/13/2026: $4.7641 per share Sale price 04/10/2026: $4.7180 per share +2 more

5 metrics

Shares sold 16,631 shares Total ordinary shares sold on April 10 and 13, 2026

Sale price 04/13/2026 $4.7641 per share Weighted average price for 4,399 shares sold

Sale price 04/10/2026 $4.7180 per share Weighted average price for two sales totaling 12,232 shares

Post-sale holdings 3,707,569 shares Ordinary shares directly held by CEO after transactions

Intraday price ranges $4.60–$4.88 per share Ranges for multiple transaction prices described in footnotes

Key Terms

Rule 10b5-1(c), restricted stock units, weighted average price, open-market sale

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) CEO Jurgi Camblong report in this Form 4?

CEO Jurgi Camblong reported selling 16,631 ordinary shares of SOPHiA GENETICS in open-market transactions. The sales occurred on April 10 and 13, 2026, at weighted average prices in the mid-$4 range per share, and were linked to tax obligations on vesting awards.

At what prices were the SOPHiA GENETICS (SOPH) shares sold by the CEO?

The reported sales used weighted average prices around $4.72–$4.76 per share. Footnotes explain individual trades occurred in ranges from $4.60 to $4.77 and from $4.64 to $4.88 per share, with full price breakdowns available on request from the company or regulators.

Why did the SOPHiA GENETICS (SOPH) CEO sell 16,631 shares?

The filing states the CEO’s share sales were to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. These transactions were carried out automatically under a pre-established Rule 10b5-1(c) trading plan, rather than as discretionary trades.

How many SOPHiA GENETICS (SOPH) shares does the CEO hold after these sales?

Following the reported transactions, CEO Jurgi Camblong directly holds 3,707,569 ordinary shares of SOPHiA GENETICS. This post-transaction balance in the Form 4 shows the CEO retains a substantial equity position in the company despite the tax-related share sales disclosed.

Were the SOPHiA GENETICS (SOPH) CEO’s share sales under a Rule 10b5-1 plan?

Yes. Footnotes specify that the transactions were made under a duly adopted Rule 10b5-1(c) trading plan. Such plans pre-schedule trades, meaning the timing of these tax-related share sales was determined in advance rather than based on contemporaneous market or company-specific developments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/10/2026		S		8,500(1)	D	$4.718(2)	3,715,700	D
Ordinary Shares	04/10/2026		S		3,732(3)	D	$4.718(2)	3,711,968	D
Ordinary Shares	04/13/2026		S		4,399(3)	D	$4.7641(4)	3,707,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.64 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)